Clinical trials: Immune Checkpoint Inhibitor-Induced Dermatitis, open to volunteers
Immune Checkpoint Inhibitor-Induced Dermatitis
JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis
Currently, the principal strategy for immune checkpoint inhibitors (ICI)-related dermatitis include systemic use of corticosteroids, which can impair the efficacy of preceding ICIs treatment.
- Trial name
- NCT07530224
- Testing
- treated with JAK inhibitors orally for 28 days
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shixiu Wu
HCC - Hepatocellular Carcinoma, Immunotherapy
Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals
This study aims to evaluate the response to immunotherapy in HCC, assess the toxicity profile and measure overall survival within the study period.
- Conditions
- HCC - Hepatocellular Carcinoma, Immunotherapy, Immune Checkpoint Therapy, Immune Checkpoint Inhibitor-Induced Dermatitis
- Trial name
- NCT07088081
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University